Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Sacituzumab govitecan · 1 trial · 1 indication
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
| Arm | Type | Description |
|---|---|---|
| Treatment with Naxitamab and Sacituzumab Govitecan IV Q3W | EXPERIMENTAL | Patients receive naxitamab IV on days 2, 4, and 6 of cycles 1-8 and sacituzumab govitecan IV days 1 and 8 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. |
| Name | Type | Description |
|---|---|---|
| Sacituzumab govitecan | DRUG | Given by IV |
| Naxitamab | DRUG | Given by IV |
Inclusion criteria * Male and female participants aged 18 years or older and able to understand and give written informed consent * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 (for the phase I portion of the study) and ECOG performance status of 0-2 (for the phase I...
Sacituzumab govitecan is being studied for the treatment of metastatic triple-negative breast cancer (TNBC). It is currently in Phase 1 clinical development as an investigational therapy for this condition. The drug is being evaluated in a clinical trial enrolling patients with metastatic TNBC.
Sacituzumab govitecan is an antibody-based therapy, classified as a -mab (antibody). It is being studied in metastatic triple-negative breast cancer. The specific molecular target is not disclosed in the available information.
Sacituzumab govitecan is being developed by Y-mAbs Therapeutics, Inc., a biopharmaceutical company traded under the ticker symbol YMAB. The company is conducting a Phase 1 clinical trial of the drug in patients with metastatic triple-negative breast cancer.
Sacituzumab govitecan is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting patients with metastatic triple-negative breast cancer.
Sacituzumab govitecan is being studied in a Phase 1 clinical trial with the identifier NCT07011654. The trial is titled 'Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)' and is currently recruiting participants in the United States.
Sacituzumab govitecan is not the same as Naxitamab. They are distinct drugs being studied together in a combination clinical trial for metastatic triple-negative breast cancer. The trial evaluates both agents in patients with this condition.